Fragment-Based Drug Discovery 2014

Fragment-based approaches for finding potential new medical therapies are now a part of many drug discovery programs. There are at least 25 disclosed drug candidates forging ahead in clinical development whose origins can be traced to fragment-based screening campaigns. However medicinal chemists, especially in larger companies with high throughput screening departments, have other sources for ‘hits’ to optimize into lead drug candidates. What is the exact role and usefulness of fragment-based screening nowadays? How is it changing? How can it be improved? How can it be better integrated or used synergistically with other approaches? Join your discovery chemistry peers at Cambridge Healthtech Institute’s ninth annual Fragment-Based Drug Discovery meeting to discuss these questions and hear presentations about the ever present challenge for medicinal chemists: optimization strategies to get to better drugs from fragment hits.